The price-to-earnings ratio for Haemonetics Corp. (NYSE: HAE) is above average at 37.57x, Company’s 36-month beta value is 0.40.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 5 as “hold,” and 1 as “sell.”
The public float for HAE is 50.29M, and currently, short sellers hold a 4.45% ratio of that floaft. The average trading volume of HAE on May 10, 2024 was 479.85K shares.
HAE) stock’s latest price update
Haemonetics Corp. (NYSE: HAE)’s stock price has gone decline by -0.70 in comparison to its previous close of 93.25, however, the company has experienced a -0.78% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2024-05-09 that The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
HAE’s Market Performance
HAE’s stock has fallen by -0.78% in the past week, with a monthly rise of 7.49% and a quarterly rise of 18.55%. The volatility ratio for the week is 3.48% while the volatility levels for the last 30 days are 2.82% for Haemonetics Corp. The simple moving average for the past 20 days is 4.57% for HAE’s stock, with a 8.93% simple moving average for the past 200 days.
Analysts’ Opinion of HAE
Many brokerage firms have already submitted their reports for HAE stocks, with Mizuho repeating the rating for HAE by listing it as a “Buy.” The predicted price for HAE in the upcoming period, according to Mizuho is $90 based on the research report published on October 13, 2022 of the previous year 2022.
Citigroup gave a rating of “Neutral” to HAE, setting the target price at $59 in the report published on December 15th of the previous year.
HAE Trading at 11.07% from the 50-Day Moving Average
After a stumble in the market that brought HAE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.66% of loss for the given period.
Volatility was left at 2.82%, however, over the last 30 days, the volatility rate increased by 3.48%, as shares surge +7.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.68% upper at present.
During the last 5 trading sessions, HAE fell by -0.78%, which changed the moving average for the period of 200-days by +0.89% in comparison to the 20-day moving average, which settled at $88.86. In addition, Haemonetics Corp. saw 8.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HAE starting from Lingamneni Anila, who sale 2,305 shares at the price of $95.00 back on May 06 ’24. After this action, Lingamneni Anila now owns 12,295 shares of Haemonetics Corp., valued at $218,975 using the latest closing price.
Strong Stewart W, the President, Global Hospital of Haemonetics Corp., sale 228 shares at $90.65 during a trade that took place back on Sep 12 ’23, which means that Strong Stewart W is holding 16,221 shares at $20,668 based on the most recent closing price.
Stock Fundamentals for HAE
Current profitability levels for the company are sitting at:
- 0.13 for the present operating margin
- 0.53 for the gross margin
The net margin for Haemonetics Corp. stands at 0.1. The total capital return value is set at 0.09. Equity return is now at value 14.72, with 6.21 for asset returns.
Based on Haemonetics Corp. (HAE), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at 0.23. The debt to equity ratio resting at 0.92. The interest coverage ratio of the stock is 18.67.
Currently, EBITDA for the company is 249.34 million with net debt to EBITDA at 2.62. When we switch over and look at the enterprise to sales, we see a ratio of 4.24. The receivables turnover for the company is 6.0for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.92.
Conclusion
In a nutshell, Haemonetics Corp. (HAE) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
